Evidence map›Paper›PMID 41896536›Full record

ArticleNature communications2026

Restoring early postnatal synaptic dysregulation rescues motor neuron degeneration in a mouse model of Spinal and Bulbar Muscular Atrophy.

Tomoki Hirunagi, Kentaro Sahashi, Madoka Iida, Kazunari Onodera, Satoshi Yokoi, Yosuke Ogura, Genki Tohnai, Kenji Sakakibara, Kentaro Maeda, C Frank Bennett and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tomoki HirunagiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0002-1948-0126
Kentaro SahashiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan. sahashi.kentaro.r7@f.mail.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0003-3256-9659
Madoka IidaDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0002-3394-9760
Kazunari OnoderaDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Satoshi YokoiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yosuke OguraDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0002-5251-9176
Genki TohnaiDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0009-0007-3888-1201
Kenji SakakibaraDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kentaro MaedaDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
C Frank BennettIonis Pharmaceuticals, Carlsbad, CA, USA.
Yohei OkadaDepartment of Neural iPSC Research, Institute for Medical Science of Aging, Aichi Medical University School of Medicine, Nagakute, Japan.ORCID http://orcid.org/0000-0001-5253-8556
Masahisa KatsunoDepartment of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan. katsuno.masahisa.i1@f.mail.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0001-9453-9311

Funding

Japan Agency for Medical Research and Development (AMED) JP22am0401007Japan Agency for Medical Research and Development (AMED) JP22bm0804020Japan Agency for Medical Research and Development (AMED) JP22nk0101575Japan Agency for Medical Research and Development (AMED) P25bm1423003MEXT | Japan Society for the Promotion of Science (JSPS) JP20H00527MEXT | Japan Society for the Promotion of Science (JSPS) JP23H00420MEXT | Japan Society for the Promotion of Science (JSPS) JP23K24249MEXT | Japan Society for the Promotion of Science (JSPS) JP24K18683MEXT | Japan Society for the Promotion of Science (JSPS) JP24K18712MEXT | Japan Society for the Promotion of Science (JSPS) JP25K02585
6 · The paper itself

Abstract

Spinal and bulbar muscular atrophy (SBMA) is an adult-onset neurodegenerative disorder caused by expansion of a polyglutamine tract in the androgen receptor (AR). Here, we show that polyglutamine-expanded AR accumulates in the nucleus of motor neurons and induces aberrant upregulation of glutamatergic synaptic genes through dysfunction of the master transcriptional repressor REST during early postnatal development in a mouse model of SBMA (AR-97Q mice). Reducing mutant AR or restoring REST function using antisense oligonucleotides during the neonatal period attenuated the upregulation of glutamatergic synaptic genes and ameliorated the disease phenotype and histopathology in AR-97Q mice. Furthermore, we observed increased calcium activity in induced pluripotent stem cell-derived motor neurons from SBMA patients compared to those from healthy controls, reflecting neuronal hyperexcitability. Late-onset neurodegeneration in SBMA is attributable to early synaptic defects and the resulting hyperexcitability of motor neurons, which may represent therapeutic targets.

Indexed as

Motor NeuronsMuscular Atrophy, SpinalNerve DegenerationReceptors, AndrogenSynapsesAnimalsDisease Models, AnimalFemaleHumansInduced Pluripotent Stem CellsMaleMiceMice, TransgenicOligonucleotides, AntisensePeptidesRepressor ProteinsAR protein, mouseOligonucleotides, AntisensePeptidespolyglutamineReceptors, AndrogenRepressor Proteins

Identifiers

PMID41896536
PMCPMC13031292

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.